A cost evaluation of treatment alternatives in mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Turkey

Basit Öğe Kaydı
dc.contributor.authorDundar S.
dc.contributor.authorZülfikar B.
dc.contributor.authorKavakli K.
dc.contributor.authorGönen C.
dc.contributor.authorZülfikar H.
dc.contributor.authorYilmaz D.
dc.contributor.authorHart W.M.
dc.contributor.authorSümen A.
dc.contributor.authorTuna S.
dc.contributor.authorKaramalis M.
dc.date.accessioned2019-10-27T00:10:57Z
dc.date.available2019-10-27T00:10:57Z
dc.date.issued2005
dc.departmentEge Üniversitesien_US
dc.description.abstractA decision-analysis model was constructed to assess total direct health care costs of four current first-line treatment options for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Turkey: recombinant activated Factor VII (rFVIIa); high-dose Factor VIII; prothrombin complex concentrate (PCC); and activated PCC (aPCC). Resource utilisation was based on a retrospective analysis of 105 bleeding episodes treated during the period January 1996 to December 2002. Clinical outcomes were derived from a combination of the retrospective patient data and literature review, both validated by an expert panel of Turkish haematologists. rFVIIa was more effective and resolved bleeds more quickly than any of the alternatives. rFVIIa and PCC were associated with similar direct treatment costs that were relatively lower than those compared with the other options. Given the better efficacy, rFVIIa should be considered the preferred treatment option in the management of haemophilia patients with inhibitors in Turkey. © 2005 T&F Informa UK Ltd.en_US
dc.identifier.endpage54en_US
dc.identifier.issn1369698X
dc.identifier.issn1369-698Xen_US
dc.identifier.issue45-54en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage45en_US
dc.identifier.urihttps://hdl.handle.net/11454/22080
dc.identifier.volume8en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.relation.ispartofJournal of Medical Economicsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBleeding episodesen_US
dc.subjectCostsen_US
dc.subjectHaemophiliaen_US
dc.subjectInhibitoren_US
dc.subjectRecombinant activated Factor VIIaen_US
dc.titleA cost evaluation of treatment alternatives in mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Turkeyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu